SEARCH

SEARCH BY CITATION

References. (*) Denotes article included in the meta-analysis

  • *Adibhatla R. M. and Hatcher J. F. (2007) Role of lipids in brain injury and diseases. Future Lipidol. 2, 403422.
  • Adibhatla R. M. and Hatcher J. F. (2010) Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 12, 125169.
  • *Adibhatla R. M., Hatcher J. F. and Tureyen K. (2005) CDP-choline liposomes provide significant reduction in infarction over free CDP-choline in stroke. Brain Res. 1058, 193197.
  • Alonso de Lecinana M., Gutierrez M., Roda J. M., Carceller F. and Diez-Tejedor E. (2006) Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke. J. Neurol. Sci. 247, 121129.
  • Andersen M., Overgaard K., Meden P., Boysen G. and Choi S. C. (1999) Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke 30, 14641471.
  • *Aronowski J., Strong R. and Grotta J. C. (1996) Citicoline for treatment of experimental focal ischemia: histologic and behavioural outcome. Neurol. Res. 18, 570574.
  • *Ataus S. A., Onal M. Z., Ozdem S. S., Locke K. W. and Balkan S. (2004) The effects of citicoline and lamotrigine alone and in combination following permanent middle cerebral artery occlusion in rats. Int. J. Neurosci. 114, 183196.
  • Bolland K., Whitehead J., Cobo E. and Secades J. J. (2009) Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline. Pharm. Stat. 8, 136149.
  • Clark W. M., Williams B. J., Selzer K. A., Zweifler R. M., Sabounjian L. A. and Gammans R. E. (1999) A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 30, 25922597.
  • Clark W. M., Wechsler L. R., Sabounjian L. A. and Schwiderski U. E. (2001) A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 57, 15951602.
  • Cohen M. M. (1973) Biochemistry of cerebral anoxia, hypoxia and ischemia. Monogr. Neural Sci. 1, 149.
  • Davalos A., Castillo J., Alvarez-Sabin J. et al. (2002) Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke 33, 28502857.
  • Davalos A., Alvarez-Sabín J., Castillo J. et al. (2012) Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 28, 349357.
  • De Keyser J., Sulter G. and Luiten P. G. (1999) Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci. 22, 535450.
  • DerSimonian R. and Laird N. (1986) Meta-analysis in clinical trials. Control. Clin. Trials 7, 177188.
  • Fisher M. (1997) Characterizing the target of acute stroke therapy. Stroke 28, 866872.
  • Frantzias J., Sena E. S., Macleod M. R. and Al-Shahi Salman R. (2011) Treatment of intracerebral hemorrhage in animal models: meta-analysis. Ann. Neurol. 69, 389399.
  • Gladstone D. J., Black S. E. and Hakim A. M. (2002) Toward wisdom from failure: lessons from neuroprotective stroke trials and new directions. Stroke 33, 21232136.
  • Goto Y., Okamoto S., Yonekawa Y., Taki W., Kikuchi H., Handa H. and Kito M. (1988) Degradation of phospholipid molecular species during experimental cerebral ischemia in rats. Stroke 19, 728735.
  • *Han H., Xia Z., Chen H., Hou C. and Li W. (2011) Simple diffusion delivery via brain interstitial route for the treatment of cerebral ischemia. Sci. China Life Sci. 54, 235239.
  • *Hurtado O., Moro M. A., Cardenas A. et al. (2005) Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. Neurobiol. Dis. 18, 336345.
  • *Hurtado O., Cardenas A., Pradillo J. M., Morales J. R., Ortego F., Sobrino T., Castillo J., Moro M. A. and Lizasoain I. (2007) A chronic treatment with CDP-choline improves functional recovery and increases neuronal plasticity after experimental stroke. Neurobiol. Dis. 26, 105111.
  • *Hurtado O., Pradillo J. M., Fernandez-Lopez D., Morales J. R., Sobrino T., Castillo J., Alborch E., Moro M. A. and Lizasoain I. (2008) Delayed post-ischemic administration of CDP-choline increases EAAT2 association to lipid rafts and affords neuroprotection in experimental stroke. Neurobiol. Dis. 29, 123131.
  • Kakihana M., Fukuda N., Suno M. and Nagaoka A. (1988) Effects of CDP-choline on neurologic deficits and cerebral glucose metabolism in a rat model of cerebral ischemia. Stroke 19, 217222.
  • Macleod M. R., O'Collins T., Howells D. W. and Donnan G. A. (2004) Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 35, 12031208.
  • *Onal M. Z., Li F., Tatlisumak T., Locke K. W., Sandage B. W. and Fisher M. (1997) Synergistic effects of citicoline and MK-801 in temporary experimental focal ischemia in rats. Stroke 28, 10601065.
  • *Onal M. A., Ataus S., Nizamoglu E., Locke K. and Balkan S. (2000) Synergistic effects of citicoline and lamotrigine in permanent middle cerebral artery occlusion in rats. In 52nd Annual Meeting of the American Academy of Neurology, San Diego, USA.
  • Saver J. L. (2008) Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair. Rev. Neurol. Dis. 5, 167177.
  • *Schabitz W. R., Weber J., Takano K., Sandage B. W., Locke K. W. and Fisher M. (1996) The effects of prolonged treatment with citicoline in temporary experimental focal ischemia. J. Neurol. Sci. 138, 2125.
  • *Schabitz W. R., Li F., Irie K., Sandage B. W., Locke K. W. and Fisher M. (1999) Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia. Stroke 30, 42732.
  • Secades J. J. (2002) CDP-choline: updated pharmacological and clinical review. Methods Find. Exp. Clin. Pharmacol. 24, 156.
  • Sena E. S., van der Worp H. B., Bath P. M., Howells D. W. and Macleod M. R. (2010) Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol. 8, e1000344.
  • *Shuaib A., Yang Y. and Li Q. (2000) Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase. Exp. Neurol. 161, 733739.
  • *Sobrado M., Lopez M. G., Carceller F., Garcia A. G. and Roda J. M. (2003) Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase Bcl-2 expression after focal cerebral ischemia. Neuroscience 118, 107113.
  • STAIR. (1999) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30, 27522758.
  • Warach S., Pettigrew L. C., Dashe J. F., Pullicino P., Lefkowitz D. M., Sabounjian L., Harnett K., Schwiderski U. and Gammans R. (2000) Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Ann. Neurol. 48, 713722.
  • *Weber J., Schabitz W. R., Takano K., Sandage B. N., Locke K. W. and Fisher M. (1995) Effects of citicoline on infarct volume, mortality and behavioral outcome after temporary focal ischemia. In IVth European Stroke Conference, Burdeaux, France.